Nguyen Van Hung (NTP, Viet Nam)

Similar documents
Peggy Leslie-Smith, RN

Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines

Latent tuberculosis infection

Programmatic management of latent TB infection: Global perspective and updates. Haileyesus Getahun, MD, MPH, PhD.

LATENT TUBERCULOSIS. Robert F. Tyree, MD

TB Prevention Who and How to Screen

Programmatic management of LTBI : a two pronged approach for ending the TB epidemic. Haileyesus Getahun Global TB Programme WHO/HQ

TB Intensive Tyler, Texas December 2-4, 2008

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Targeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease

Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast

Diagnosis Latent Tuberculosis. Disclosures. Case

New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers

Tuberculosis Populations at Risk

These recommendations will remain in effect until the national shortage of PPD solution has abated.

TB in Corrections Phoenix, Arizona

Approaches to LTBI Diagnosis

Northwestern Polytechnic University

Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Preventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers. Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program

INTENSIFIED TB CASE FINDING

Richard O Brien, Consultant, FIND 3 rd Global Symposium on IGRAs Waikoloa, Hawaii, 13 January 2012

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant

LTBI monitoring and evaluation in the Netherlands

TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of

Self-Study Modules on Tuberculosis

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Making the Diagnosis of Tuberculosis

결핵노출접촉자감염관리 서울아산병원감염내과 김성한

Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014

Expanding Latent Tuberculosis Infection Testing and Treatment to Accelerate Tuberculosis Elimination

Report on WHO Policy Statements

CUSOM Student Health Immunization Requirements

Table 9. Policy for Tuberculosis Surveillance and Screening

TB Intensive Houston, Texas October 15-17, 2013

2016 OPAM Mid-Year Educational Conference, Sponsored by AOCOPM Sunday, March 13, 2016

New Tuberculosis Guidelines. Jason Stout, MD, MHS

CDC IMMIGRATION REQUIREMENTS:

Diagnosis & Management of Latent TB Infection

TB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014

Asking the Right Questions. A Visual Guide to Tuberculosis Case Management for Nurses. Reference Guide

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

New Standards for an Old Disease:

Latent Tuberculosis Best Practices

Testing for TB. Bart Van Berckelaer Territory Manager Benelux. Subtitle

Technical Bulletin No. 172

Screening for Tuberculosis Infection. Harlingen, TX. Linda Dooley, MD has the following disclosures to make:

TB is Global. Latent TB Infection (LTBI) Sharing the Care: Working Together. September 24, 2014

Monitoring & evaluation LTBI management in the Netherlands. Key lessons.

Primer on Tuberculosis (TB) in the United States

Detecting latent tuberculosis using interferon gamma release assays (IGRA)

Using Interferon Gamma Release Assays for Diagnosis of TB Infection

TB Intensive San Antonio, Texas November 11 14, 2014

Conflict of Interest Disclosures:

A Mobile Health Intervention Utilizing Community Partnership to Improve Access to Latent Tuberculosis Infection Treatment

What Is New in Combination TB Prevention? Lisa J. Nelson Treatment and Care (TAC) Team HIV Department WHO HQ

Tuberculosis Tools: A Clinical Update

CHAPTER 3: DEFINITION OF TERMS

TB Epidemiology. Richard E. Chaisson, MD Johns Hopkins University Center for Tuberculosis Research

Student Health Requirements Master of Arts, Biomedical Sciences Program

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

Latest developments in WHO estimates of TB disease burden

LTBI: Who to Test & When to Treat

The Most Widely Misunderstood Test of All

Diagnosis of tuberculosis

Management of Pediatric Tuberculosis in New Jersey

Principle of Tuberculosis Control. CHIANG Chen-Yuan MD, MPH, DrPhilos

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis

Research Article Change in the Prevalence of Testing for Latent Tuberculosis Infection in the United States:

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

Community pharmacy-based tuberculosis skin testing

11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016

Communicable Disease Control Manual Chapter 4: Tuberculosis

Contracts Carla Chee, MHS May 8, 2012

Latent TB Infection (LTBI) Strategies for Detection and Management

Contact Investigation

Tuberculosis Update. Topics to be Addressed

2017/2018 Annual Volunteer Tuberculosis Notice

Thorax Online First, published on December 8, 2009 as /thx

Scaling up collaborative TB/HIV activities: achievements, challenges, and opportunities in Viet Nam

Revised Technical Instructions for Civil Surgeons. October 9, 2018

Clinical Policy Title: Interferon-gamma release assays for tuberculosis screening

Self-Study Modules on Tuberculosis

Tuberculosis Procedure ICPr016. Table of Contents

Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013

Yakima Health District BULLETIN

Background paper number 7

Identifying TB co-infection : new approaches?

Use of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING -

Detection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges

MEMORANDUM. Re: Guidance for follow-up of newly-arrived individual with Class B1 Tuberculosis Pulmonary Tuberculosis, no treatment

Transcription:

Technical Consultation Meeting on the Programmatic Management of Latent Tuberculosis Infection 31 August-1 September 2017, Seoul, Republic Korea Adopting new LTBI diagnostics at country level: perspective from Viet Nam LTBI Nguyen Van Hung (NTP, Viet Nam)

Vietnam economic situation http://www.focus-economics.com/countries/vietnam Vietnam 2009: lower- middle - income country (WB : 1000 4000 USD per capita) Vietnam 2031 (ADB): upper- middle - income country (WB: 8000 9.800 USD per capita) All spending on healthcare services accounts for 5.8% GDP, the highest level in ASEAN

Vietnam TB epidermiology (1) Vietnam remains a country with high TB burden, ranked 15 th out of 30 countries with highest TB burden, (WHO Report 2016). High TB buden Year Est. Prevalence per 100,000 2011 323 2012 218 2013 209 2014 198 Annual declining prevalence: 4,6%

Vietnam TB epidermiology (2) VN ranked 15 th out of 30 countries with highest burden of MDR-TB (WHO Report 2016). High burden of MDR TB MDR TB burden DRS 3 (06-07) DRS 4 (11-12) MDR rate among new TB patients MDR rate among retreated patients The No of MDR-TB patients among new TB patients The No of MDR-TB patients among retreated patients Total No of MDR-TB patients among TB patients XDR-TB/MDR-TB 2.7 % 4.0 % 19% 23.3 2000 3060 1700 2104 3700 5200 5.6%

Political commitment with adequate resources for TB care and prevention BOX 1.5 HIGH-LEVEL COMMITMENT: FIRST STEPS FORWARD IN VIETNAM When endorsing the new End TB Strategy at the WHA, Viet Nam s representative declared that, inspired by ongoing global discussions leading to the WHA resolution, the country had already launched its post-2015 national TB strategy. This sets ambitious targets for 2020 and 2030, in line with the End TB Strategy and targets. High-level commitment was evident throughout the Viet Nam strategy s development. First, the strategy was launched by the Deputy Prime Minister at a gathering of all stakeholders

Vietnam TB diagnostic System NTP: Strong and stable system for TB diagnosis District level: more than 700 TB units Provincial level: 63 (45 out of 63 provinces have established Tuberculosis and Pulmonary Diseases hospitals). Central Level 05 Reginal Hospitals: PNT, DN, CT, 71, 74 01 National Hospitals: National Lung Hospital General Health Sytem involving in TB activity at all levels

Implementing national latent TB management services (1) Key documentations WHO guidelines: National LTBI policy based on adaptation of WHO RECOMMENDATIONS FOR THE MANAGEMENT OF LTBI COUNTRY GROUP Resource-limited and other middle-income countries with an estimated TB incidence rate of more than 100 per 100 000 population Risk population and Clinical indications - patients The End TB Strategy: As countries adapt and implement the End TB Strategy includes a global target for LTBI management (ID5. LTBI TREATMENT COVERAGE >= 90%; ID6. CONTACT INVESTIGATION COVERAGE 90%) CDC: www.cdc.gov/tb;

Implementing national latent TB management services (2) Tests for the diagnosis of latent TB tuberculin skin tests (TST) interferon-gamma release assays (IGRA) Quantiferon TB Gold Plus (QFT-Plus) T-SPOT TB test Which test to use But We still need a test for incipient TB

Implementing national latent TB management services (3) Selecting a Test to Detect TB Infection TST advantages of the TST: inexpensive costs widely available does not require complicated or expensive laboratory equipment. staff can be easily trained. Disadvantages: requires patient return to the clinic 2-3 days after administration of the injection, results are based on observation by trained staff multiple factors that can affect TST. potential sources for false positives: nontuberculous mycobacterium (NTM) infection and prior BCG vaccination false negatives may occur in particular patient subgroups

Implementing national latent TB management services (4) Selecting a Test to Detect TB Infection IGRA Advantages of IGRAs include the following: Requires a single patient visit to conduct the test (preferred method of testing for goup of people who have poor rates of return) Does not cause booster phenomenon. Laboratory test not affected by health care worker perception or bias. Results can be available within 24 hours. Unaffected by BCG and most environmental mycobacteria. Limitations of IGRAs include the following: Blood sample must be processed within 8-30 hours after collection. Limited data exist on use in groups such as children younger than 5 years of age, persons recently exposed to TB, immunocompromised persons, and those who will be tested repeatedly (serial testing). significantly greater cost (including the need for specialized equipment) as compared to the TST

Implementing national latent TB management services (5) Who should be tested for LTBI Who to test patients who are at risk for LTBI and would benefit from treatment (increased risk for developing active TB) Who should NOT be tested Generally, testing with TST and IGRAs should be avoided for persons at low risk for both latent infection and progression to active TB (unless they are likely to be at increased risk in the future)

Implementing national latent TB diagnosis services (6) IGRA lab system District level: transfering. Provincial level: 63 T-SPOT TB Labs (45 out of 63 provinces have established Tuberculosis and Pulmonary Diseases hospitals) Central Level: 6 QFT-Plus Labs 05 Reginal Hospital: PNT, DN, CT, 71, 74 01 National Hospital: National Lung Hospital (may have T-SPOT TB lab at NLH for training) Vietnam NTP negotiated price Cover by Health insurance system

Implementing national latent TB management services (7) Current implementation IPT Treatment People living with HIV Household or close contacts children < 5 years QI/ 2017: 1003 2016: 3515 (children subject to IPT in 12 provincies/ GLF) Next step: Expanding IPT treatment in other provincies LTBI Research: ACT4: Enhancing the public health impact of latent TB infection diagnosis and treatment: A pragmatic cluster randomized trial V-QUIN TRIAL: A randomized controlled trial of levofloxacin for the prevention of multi drug-resistant tuberculosis among household contacts of patients with MDR-TB

Implementing national latent TB management services(8) In planing: IGRA positive (No symptoms or physical findings suggestive of TB disease. Chest radiograph is typically normal, respiratory specimens are smear and culture negative if done) patients initiating anti-tumour necrosis factor (TNF) treatment, patients receiving dialysis, patients preparing for organ or haematologic transplantation, patients with silicosis

Implementing national latent TB management services (9) In planing IGRA positive (No symptoms or physical findings suggestive of TB disease. Chest radiograph is typically normal, respiratory specimens are smear and culture negative if done) Household or close contacts, aged >= 5 years Prisoners Health workers working in environments with potential TB exposure Immigrants from high TB burden countries Homeless persons Illicit drug users

Implementing national latent TB management services (10) In planing IGRA positive (No symptoms or physical findings suggestive of TB disease. Chest radiograph is typically normal, respiratory specimens are smear and culture negative if done) Any contact with index case of XDR TB Any person who excluded from TB diagnosis among TB subspects for case finding Thanks for attention